Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trialLancet Oncol 2022 Sep 02;[EPub Ahead of Print], F Saad, A Thiery-Vuillemin, P Wiechno, B Alekseev, N Sala, R Jones, I Kocak, VE Chiuri, J Jassem, A Fléchon, C Redfern, J Kang, J Burgents, C Gresty, A Degboe, NW Clarke
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.